Deaths / year
—
GBD (indicative unless refreshed)
DALYs / year
—
GBD
Pathogen
Polymicrobial
Post-infectious
Lasting sequela
Persistent symptoms
n/a
Added to WHO NTD list December 2023 (21st NTD).
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Severe facial disfigurement, trismus, functional (eating/speech) impairment in survivors
Classification
Lasting sequela
Onset
post-acute (survivors)
Persistent-symptom %
not quantified as a single figure (see notes)
Source: Srour 2015; WHO
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Nutrition & oral hygiene programs | Prevention | Approved | Malnutrition is major risk factor | WHO / MSF |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Amoxicillin–clavulanate | Antibiotic | Approved | Acute necrotizing infection | WHO EML / standard of care |
| Metronidazole | Antibiotic | Approved | Anaerobic coverage | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Nutritional rehabilitation + reconstructive surgery | Supportive | Approved | Survivor reconstruction | WHO / MSF protocols |
Associated drug targets (Open Targets): GCG, CAT
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0017124 · Updated 2026-07-10. Associations, not a diagnostic test.